The trial aims to assess the impact of the drug on menstrual events, as well as liver function.
In the trial, the patients will be administered with 12mg of Proellex per day.
In earlier study, Proellex demonstrated improvement as compared to placebo in all three elements of pain typically associated with the disorder; dysmenorrhea (menstrual pain), non menstrual pelvic pain, and dyspareunia (pain during sex).